NasdaqCM - Delayed Quote USD

Estrella Immunopharma, Inc. (ESLA)

0.6393 -0.0894 (-12.27%)

At close: October 30 at 4:00:01 PM EDT

Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors

Business Wire 6d ago

ESLA
-12.27%
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase

Business Wire 16d ago

ESLA
-12.27%
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Business Wire 17d ago

ESLA
-12.27%
ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial

Zacks Small Cap Research 2mo ago

ESLA
-12.27%
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Business Wire 2mo ago

ESLA
-12.27%
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Business Wire 3mo ago

ESLA
-12.27%
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma

Business Wire 3mo ago

ESLA
-12.27%
ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL

Zacks Small Cap Research 8mo ago

ESLA
-12.27%
ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?

Zacks Small Cap Research 3mo ago

ESLA
-12.27%
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Business Wire 2mo ago

ESLA
-12.27%
ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T

Zacks Small Cap Research 7mo ago

ESLA
-12.27%
ACLX

GILD

U.S. markets closed

Estrella Immunopharma, Inc. (ESLA)

Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors

Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase

Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma

ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL

ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T